PDL BioPharma Inc

PDL BioPharma — UBS Global Healthcare Conference 2019

27 slides from PDL BioPharma's conference presentation, May 21, 2019

  1. Slide 1: UBS Global Healthcare Conference

    Slide 1: UBS Global Healthcare Conference

    PDL UBS Global Healthcare Conference May 21, 2019 PDL BioPharma, Inc. Nasdaq: PDLI PDL.com

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual

  3. Slide 3: PDL's Mission

    Slide 3: PDL's Mission

    PDL’s Mission Improve the lives of patients and create value for our shareholders and our people by applying our capital and expertise for the successful development and commercialization of innovative therapeutics by our partner companies. PDL

  4. Slide 4: PDL's Strategy

    Slide 4: PDL's Strategy

    PDL’s Strategy We deliver on our Mission by entering into strategic transactions involving innovative late clinical-stage or early commercial-stage therapeutics with attractive revenue growth potential. PDL

  5. Slide 5: What We Are Looking For?

    Slide 5: What We Are Looking For?

    What We Are Looking For? Seeking biotech and pharma assets that can benefit from accessing our capital and expertise + Differentiated commercial-stage products and/or companies « Innovative late development-stage assets * High-quality, collaborative teams we can build on Focus on strategic therapy a

  6. Slide 6: Our Strengths in the Competition for Assets

    Slide 6: Our Strengths in the Competition for Assets

    Our Strengths in the Competition for Assets = Strong, liquid balance sheet that can be quickly deployed * $366 million in cash at 3/31/19 * $376 million in royalty rights assets (fair value at 3/31/19) expected to generate $550+ million in cash flows through 2026 = Expertise in sourcing and evaluati

  7. Slide 7: Leadership with Established Track Record

    Slide 7: Leadership with Established Track Record

    Leadership with Established Track Record Executive Management Dominique Monnet, President & CEO Peter Garcia, CFO Chris Stone, General Counsel Jill Jene, Ph.D., VP, Business Dev. Alan Markey, CEO, Noden Pharma Nick Curtis, CEO, LENSAR Capabilities & Accomplishments >$1 billion in completed transacti

  8. Slide 8: PDL's Strategic Portfolio

    Slide 8: PDL's Strategic Portfolio

    PDL’s Strategic Portfolio Our strategic portfolio includes: = Evofem Biosciences — Equity investment in Nasdaq-listed, clinical-stage women’s health company developing products based on its Multipurpose Vaginal pH Regulator™ (MVP-R) gel technology. + Expected to file in 4Q-2019 for U.S. FDA approval

  9. Slide 9: Evofem Biosciences

    Slide 9: Evofem Biosciences

    PDL E¥OFEM BIOSCIENCE S®

  10. Slide 10: Evofem Biosciences at a Glance

    Slide 10: Evofem Biosciences at a Glance

    10 Evofem Biosciences at a Glance E¥OFEM BIOS CLEN CE s* A Clinical Stage Biopharmaceutical Company committed to developingand commercializing innovative products to address unmet needs in women’s sexual and reproductive health Multipurpose Vaginal pH Regulator™ (MVP-R) gel technology + Non-hormonal

  11. Slide 11: Rationale for Our Investment in Evofem

    Slide 11: Rationale for Our Investment in Evofem

    " Rationale for Our Investment in Evofem Fits PDL strategic focus: Women’s health is an underserved area of strategic interest, with significant unmet needs Evofem is led by a talented, highly experienced team Amphora® is a novel product with significant near-term commercial potential: + Late-stage

  12. Slide 12: Evofem: Terms of Transaction

    Slide 12: Evofem: Terms of Transaction

    12 Evofem: Terms of Transaction Potential total investment of $60 million by PDL 18 tranche of $30 million closed on April 11% * ~6.67 million shares of Evofem, plus * ~1.67 million common stock warrants of Evofem priced at $6.38 per share = 2 tranche decision on or before June 10" « Same per share

  13. Slide 13: LENSAR

    Slide 13: LENSAR

    PDL CATARACT LASER WITH AUGMENTED REALTY

  14. Slide 14: LENSAR

    Slide 14: LENSAR

    | LENSAR = Converted debt to equity in May 2017 * Ability to utilize $116.5 million in NOLs - PDLutilized approximately $45.3 million in LENSAR NOLs in 2017 and 2018 resulting in cash tax savings of approximately $14.2 million. * Consider an exit when shareholder value is maximized = A leading globa

  15. Slide 15: LENSAR Highlights

    Slide 15: LENSAR Highlights

    15 LENSAR Highlights Leading Technology Platform Positioned for Growth >27 million cataract surgeries estimated in 2018 Integrating preop diagnostics to wirelessly transmit patient measurement data driving growth by improving efficiencies and delivering better outcomes 60-70% of cataract patients ha

  16. Slide 16: Noden Pharma

    Slide 16: Noden Pharma

    PDL NODEN y PHARMA

  17. Slide 17: Noden Pharma Overview

    Slide 17: Noden Pharma Overview

    v7 Noden Pharma Overview ” 2) Noden Pharma and Tekturna®/Rasilez® (aliskiren) were PDL’s first operational acquisitions in July 2016 Strategic rationale: + Build a global, nimble commercial platform around a differentiated but neglected, niche cardiovascular product + Terms were hedged to provide so

  18. Slide 18: Noden: Continued Focus on Profitability

    Slide 18: Noden: Continued Focus on Profitability

    Noden: Continued Focus on Profitability = Actions to increase the profitability of Tekturna® in the U.S. and mitigate the impact of generic competition include: « Launching authorized generic (AG) version of Tekturna (aliskiren) through Prasco Laboratories in anticipation of generic competition from

  19. Slide 19: Royalty Portfolio

    Slide 19: Royalty Portfolio

    PDL Royalty Portfolio

  20. Slide 20: Projected Cash Flows from Royalties

    Slide 20: Projected Cash Flows from Royalties

    Projected Cash Flows from Royalties from 2019 to 2026 Cumulative cash flows expected to exceed $550 million $100 $700 | Cis] sb € § § 38 ‘Cumulative Cash Royalties ($ millions) 20188 20196 2020E 20216 20226 20238 20248 20256 20268 Year mmm Depomed mmm UofM-Cerdelga mmm ACEI mM VixogliosiBrothers mmm

  21. Slide 21: Financials

    Slide 21: Financials

    PDL Financials

  22. Slide 22: First Quarter 2019 Financials

    Slide 22: First Quarter 2019 Financials

    First Quarter 2019 Financials (¢ mitions Key Points = Q1-2019 revenue of $38.9 million = Q1-2019 product revenues increased by 14% vs. Q1-2018 = Product revenues make up 69% of Q1-2019 revenues = Cash flows from royalty deals: * $12.3 million in Q1-2019 = Q1-2019 GAAP net income of $6.7 million = Q1

  23. Slide 23: Strong Balance Sheet

    Slide 23: Strong Balance Sheet

    Strong Balance Sheet March 31, 2019 (Sin millions) Major Assets: Cash & cash equivalents $366 Royalty rights - at fair value $376 Debt: 2.75% Convertible debt - due 12/2021 ($3.81 conversion price)’ $150 1) PDL entered into a capped call transaction to offset potential dilution subject to a cap of $

  24. Slide 24: Share Repurchase Programs

    Slide 24: Share Repurchase Programs

    24 Share Repurchase Programs » Announced a $100 million share repurchase program on September 24, 2018 As of May 9, 2019, used $80.3 million to repurchase ~24.5 million shares at an average price of $3.27 per share $19.7 million remaining under $100 million plan initiated less than one year ago » Re

  25. Slide 25: Why Invest in PDLI?

    Slide 25: Why Invest in PDLI?

    y Invest in PDLI? Executing strategy of building portfolio of actively managed healthcare assets with growth potential Accomplished executive team with the necessary expertise Significant purchasing power with $366 million in cash on the balance sheet >$550 million in cash flows expected from royalt

  26. Slide 26: Appendix

    Slide 26: Appendix

    PDL Appendix

  27. Slide 27: GAAP to Non-GAAP Reconciliation

    Slide 27: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation (in thousands) GAAP net income attributed to PDL’s shareholders as reported Adjustments: Mark-to-market adjustment to fair value assets Non-cash interest revenues Non-cash stock-based compensation expense Non-cash debt offering costs Non-cash depreciation and amortiza

Source: SEC EDGAR · 8-K filed May 21, 2019

More decks from PDL BioPharma Inc